Antiretroviral therapy in Africa
- 31 January 2004
- Vol. 328 (7434), 280-282
- https://doi.org/10.1136/bmj.328.7434.280
Abstract
We should stop and think about the risks of resistance, and ways of minimising them, before increasing access to antiretroviral therapy in AfricaKeywords
This publication has 16 references indexed in Scilit:
- High levels of adherence do not prevent accumulation of HIV drug resistance mutationsAIDS, 2003
- Adherence is not a barrier to successful antiretroviral therapy in South AfricaAIDS, 2003
- Fitness of drug resistant HIV-1: methodology and clinical implicationsDrug Resistance Updates, 2002
- Antiretroviral-Drug Resistance among Patients Recently Infected with HIVNew England Journal of Medicine, 2002
- The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up studyAIDS, 2002
- Impact of drug resistance mutations on virologic response to salvage therapyAIDS, 1999
- Randomised controlled trial of self-supervised and directly observed treatment of tuberculosisThe Lancet, 1998
- Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma ViremiaScience, 1997
- HIV viral load markers in clinical practiceNature Medicine, 1996
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989